

# Type 2 diabetes in adults: management (medicines update) Guideline update – committee meeting 8

**Date:** Thursday, 3<sup>rd</sup> June 2021

**Location:** Virtual committee meeting by Zoom

Minutes: Final

Committee members present:			
Ibrahim Abubaker	Chair	Present for notes 1 – 7	
Chirag Bakhai	GP	Present for notes 1 – 7	
Neel Basudev	GP	Present for notes 2 – 7	
Augustin Brooks	Consultant Diabetologist	Present for notes 4 – 7	
Anne Dornhorst	Consultant Diabetologist	Present for notes 1 – 7	
Hugh Gallagher	Renal Physician	Present for notes 1 – 7	
Natasha Jacques	Pharmacist	Present for notes 1 – 7	
Sallianne Kavanagh	Pharmacist	Present for notes 1 – 7	
Sharon McCarthy	Diabetes Nurse	Present for notes 1 – 7	
Nicola Milne	Diabetes Nurse	Present for notes 1 – 7	
Soon Song	Consultant Diabetologist	Present for notes 1 – 7	
Annette Swinkels	Lay member	Present for notes 1 – 7	
Corrinne Wykes	Lay member	Present for notes 1 – 7	

NICE team in attendance:			
Lucy Beggs (LB)	Technical Adviser (Health Economics)	Present for notes 1 – 7	
Rosanne Beijers (observing)	NICE/ ERS Fellow in Guideline Methodology	Present for notes 1 – 7	
Becky Chadwick	Project	Present for notes 1 – 7	
Jacqueline Durkin	Administrator	Present for notes 1 – 7	
Rupert Franklin	Guideline Commissioning Manager	Present for notes 1 – 7	
James Hall	Senior Medical Editor	Present for notes 1 – 7	
Marie Harrisingh (MH)	Senior Technical Analyst	Present for notes 1 – 7	
Thomas Jones (TJ)	Technical Analyst (Health Economics)	Present for notes 1 – 7	
Gregory Moran (GM)	Technical Analyst	Present for notes 1 – 7	

Eric Power (observing)	Programme Director - Medicines and Technologies Programme	Present for notes 1 – 7
Susan Spiers	NICE GUT Associate Director	Present for notes 1 – 7
Philip Williams	Business Analyst	Present for notes 1 – 7
Sarah Wood ( <i>Observing</i> )	Medicines Adviser	Present for notes 1 – 7

Apologies:	
Chizo Agwu	Chair
Sarah Ali	Consultant Diabetologist
Dorothy Frizelle	Mental health professional
Gosia Wamil	Cardiologist

### 1. Welcome, declarations of interest and minutes review

The Chair welcomed the Committee members and attendees to the eighth committee meeting on Type 2 diabetes in adults (medicines update).

The Chair informed the Committee that apologies had been received, noted above.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, these are noted below. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Soon Song	Committee member, Consultant Diabetologist	Selected for National Diabetes Audit Quality Improvement Collaborative to improve CVD risk in type 2 diabetes.	Direct, non- financial professional and personal	Declare and participate
Annette Swinkels	Committee member, Lay member	Patient advisory board member: Innovative Medicine Initiative project called SOPHIA. Looking at obesity and associated future health complications.	Direct, financial	Declare and participate
Anne Dornhorst	Committee member, Consultant Diabetologist	Presented a non- promotional lecture for the London Symposium, an educational diabetes event sponsored by	Direct, financial	Declare and participate

	Sanofi. Small honorarium	
	payment received.	

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

#### 2. Presentation of additional NMA outcomes

The Chair introduced Technical Analyst, Health, Greg Moran (GM), who gave a presentation to the committee summarising the additional NMA outcomes.

The Chair thanked GM for his presentation and the Committee for their feedback.

#### 3. Interpretation of Health Economic results

The Chair introduced Technical Adviser, Health Economics, Lucy Beggs (LB) and Technical Analysts, Health Economics, Thomas Jones and Kusal Lokuge, who presented a summary and interpretation of the health economic results for the guideline.

The Chair thanked LB, TJ and KL for their presentations and the Committee for their feedback.

#### 4. Presentation of Health Economic results

Following a short break, Technical Adviser, Health Economics, Lucy Beggs (LB) and Technical Analysts, Health Economics, Thomas Jones and Kusal Lokuge continued their presentation of the health economic results for the guideline.

The Chair thanked LB, TJ and KL for their presentations and the Committee for their feedback.

## 5. Consideration of existing Technology Appraisals, NG28 recommendations and the equality impact assessment

The Chair introduced Senior Technical Analyst, Marie Harrisingh (MS), who presented an overview of the NICE Technology appraisals in type 2 diabetes, and explained how the NICE team will ensure that recommendations drafted by the committee for this guideline do not contradict the information in the Technology appraisals.

The Chair thanked MH for her presentation and the committee for their feedback.

#### 6. Recommendation drafting

The NICE technical team and the Committee discussed and drafted guideline recommendations.

#### **7. AOB**

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked if there was any other business.

As there was no further business, the Chair highlighted the date of the next meeting and brought the meeting to a close.

Date of next meeting: Monday, 7<sup>th</sup> June 2021

Location of next meeting: Virtual committee meeting by Zoom